A method for the full chemical synthesis of a semaglutide peptide, the method involving: a) Providing a first solid-phase bound peptide sequence of the formula (i) wherein: X is an amino protecting group R 1 or is an amide bonded 8-amino-3,6-dioxa-octanoic acid moiety having an R 1 protected amino group (AEEAc-R 1 ); B is a solid phase functionalized with any suitable linker structure L; and PG1 through PG5 independently are absent or are side-chain protecting groups, which may be the same as or different from any of each other; b) Removing the protecting group R 1 so as to expose a free amino group; c) Acylating said free amino group so as to obtain a second solid-phase bound peptide sequence of the formula (ii), wherein R 5 and R 6 are the same or different and are H or a carboxyl protecting group moiety; d) Removing the Alloc protecting group from the N-terminus of the solid phase bound peptide of formula (ii), so as to expose a free N-terminal alpha amino group; e) Coupling, by stepwise solid-phase peptide synthesis, the amino acid sequence R 7 -His(PG19)-Aib-Glu(PG18)-Gly-Thr(PG17)-Phe(PG16)-Thr(PG15)-Ser(PG14)-Asp(PG13)-Val-Ser(PG12)-Ser(PG11)-Tyr(PG10)-Leu-Glu(PG9)-Gly-Gln(PG8)-Ala-Ala- to said free N-terminal alpha amino group so as to obtain a solid-phase bound semaglutide peptide, wherein: PG8 to PG19 independently are absent or are side-chain protecting groups, which may be the same as or different from any of each other and/or any of PG1 to PG5; and R 7 is H or an amino protecting group, which may be the same as or different from R 1 ; and f) Cleaving the semaglutide peptide from the solid phase. a) Providing a first solid-phase bound peptide sequence of the formula (i) wherein: X is an amino protecting group R 1 or is an amide bonded 8-amino-3,6-dioxa-octanoic acid moiety having an R 1 protected amino group (AEEAc-R 1 ); B is a solid phase functionalized with any suitable linker structure L; and PG1 through PG5 independently are absent or are side-chain protecting groups, which may be the same as or different from any of each other; X is an amino protecting group R 1 or is an amide bonded 8-amino-3,6-dioxa-octanoic acid moiety having an R 1 protected amino group (AEEAc-R 1 ); B is a solid phase functionalized with any suitable linker structure L; and PG1 through PG5 independently are absent or are side-chain protecting groups, which may be the same as or different from any of each other; b) Removing the protecting group R 1 so as to expose a free amino group; c) Acylating said free amino group so as to obtain a second solid-phase bound peptide sequence of the formula (ii), wherein R 5 and R 6 are the same or different and are H or a carboxyl protecting group moiety; d) Removing the Alloc protecting group from the N-terminus of the solid phase bound peptide of formula (ii), so as to expose a free N-terminal alpha amino group; e) Coupling, by stepwise solid-phase peptide synthesis, the amino acid sequence R 7 -His(PG19)-Aib-Glu(PG18)-Gly-Thr(PG17)-Phe(PG16)-Thr(PG15)-Ser(PG14)-Asp(PG13)-Val-Ser(PG12)-Ser(PG11)-Tyr(PG10)-Leu-Glu(PG9)-Gly-Gln(PG8)-Ala-Ala- to said free N-terminal alpha amino group so as to obtain a solid-phase bound semaglutide peptide, wherein: PG8 to PG19 independently are absent or are side-chain protecting groups, which may be the same as or different from any of each other and/or any of PG1 to PG5; and R 7 is H or an amino protecting group, which may be the same as or different from R 1 ; and PG8 to PG19 independently are absent or are side-chain protecting groups, which may be the same as or different from any of each other and/or any of PG1 to PG5; and R 7 is H or an amino protecting group, which may be the same as or different from R 1 ; and f) Cleaving the semaglutide peptide from the solid phase. <EOS>